

# Vlad Ratziu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3856547/publications.pdf>

Version: 2024-02-01

186  
papers

21,204  
citations

26567

56  
h-index

10708

138  
g-index

192  
all docs

192  
docs citations

192  
times ranked

15208  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
3	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001, 357, 1069-1075.	6.3	1,316
4	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
5	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor $\alpha$ and $\delta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
6	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
7	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
8	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
9	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
10	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
11	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	5.8	478
12	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	1.8	421
13	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 6.	0.8	378
14	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952.	3.6	355
15	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016, 65, 1245-1257.	1.8	352
16	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
17	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871.	1.8	304
18	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	13.9	284

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
20	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , 2015, 15, 397-404.	4.6	267
21	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
22	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75.	1.8	228
23	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
24	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
25	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
26	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	0.8	178
27	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45.	3.6	173
28	Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013, 58, 928-935.	1.8	151
29	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
30	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	3.7	142
31	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683.	1.8	134
32	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
33	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
34	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
35	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203.	1.9	112
36	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105

#	ARTICLE	IF	CITATIONS
37	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013, 19, 57.	1.4	104
38	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
39	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055.	3.6	102
40	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest <sup>®</sup> ) and transient elastography (FibroScan <sup>®</sup> ). <i>Journal of Hepatology</i> , 2014, 60, 706-714.	1.8	101
41	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.6	101
42	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016, 65, 95-102.	1.8	91
43	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26.	2.4	91
44	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000075.	1.1	90
45	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	2.6	86
46	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635.	1.8	84
47	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889.	0.8	80
48	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
49	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
50	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
51	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	1.8	66
52	Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278.	1.8	66
53	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012, 57, 541-548.	1.8	65
54	Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 763-771.e6.	2.4	65

#	ARTICLE	IF	CITATIONS
55	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	3.6	64
56	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017, 66, 1688-1696.	6.1	59
57	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. <i>Gastroenterology</i> , 2023, 165, 5-10.	0.6	59
58	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011, 11, 39.	0.8	58
59	Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 676-685.	8.2	58
60	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018, 68, 353-361.	1.8	58
61	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56
62	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	1.8	54
63	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	0.9	53
64	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	2.6	53
65	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	0.6	53
66	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	1.8	52
67	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
68	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
69	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	1.8	45
70	Randomized Study of Asunaprevir plus Pegylated Interferon- $\alpha$ and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44
71	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest $\text{\textcircled{A}}$ ) and elastography (FibroScan $\text{\textcircled{A}}$ ). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	1.8	42
72	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 30-36.	1.0	42

#	ARTICLE	IF	CITATIONS
73	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <i>Hepatology</i> , 2019, 69, 1453-1463.	3.6	41
74	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	2.4	41
75	Liver Stiffness by Transient Elastography to Detect Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	3.6	40
76	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020, 10, 3850.	1.6	39
77	Non-alcoholic fatty liver – Perhaps not so benign. <i>Journal of Hepatology</i> , 2015, 62, 1002-1004.	1.8	38
78	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
79	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1398-1405.	1.1	35
80	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 165-178.	1.0	34
81	Non-pharmacological interventions in non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2017, 37, 90-96.	1.9	34
82	Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Microorganisms</i> , 2021, 9, 199.	1.6	33
83	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020, 2, 514-531.	5.1	31
84	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31
85	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. <i>Hepatology</i> , 2022, 76, 1360-1375.	3.6	30
86	Treatment of NASH with ursodeoxycholic acid: Pro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, S41-S45.	0.7	28
87	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	1.9	28
88	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019, 103, 28-38.	0.5	28
89	Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1000-1007.	1.9	27
90	European NAFLD Preparedness Index™ – Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	2.6	27

#	ARTICLE	IF	CITATIONS
91	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	1.8	27
92	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 992-999.e2.	2.4	26
93	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	3.7	26
94	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016, 11, e0163276.	1.1	26
95	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227.	1.8	25
96	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
97	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979.	1.8	25
98	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2022, 76, 265-274.	1.8	24
99	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020, 1, 100154.	3.3	23
100	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468.	3.6	22
101	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.	2.4	21
102	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
103	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 774030.	1.6	20
104	Is mipomersen ready for clinical implementation? A transatlantic dilemma. <i>Current Opinion in Lipidology</i> , 2013, 24, 301-306.	1.2	19
105	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 428-432.	0.6	19
106	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 59-66.	0.5	17
107	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17
108	Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 455-463.	0.7	16



#	ARTICLE	IF	CITATIONS
109	Hepatic molecular effects of rosiglitazone in human nonalcoholic steatohepatitis suggest long-term proinflammatory damage. <i>Hepatology Research</i> , 2014, 44, 1241-1247.	1.8	16
110	Back to Byzance: Querelles byzantines over NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 1134-1136.	1.8	16
111	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577.	0.8	15
112	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	1.9	15
113	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	0.6	15
114	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
115	Starting the battle to control non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015, 385, 922-924.	6.3	14
116	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015, 10, e0134302.	1.1	14
117	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon $\alpha$ -2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436.	1.4	13
118	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562.	1.1	13
119	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	1.1	13
120	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391.	0.8	13
121	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	1.4	13
122	Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 416-426.	0.7	12
123	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	0.8	12
124	NAFLD: The evolving landscape. <i>Journal of Hepatology</i> , 2018, 68, 227-229.	1.8	11
125	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
126	Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013, 58, 385-390.	1.6	10



#	ARTICLE	IF	CITATIONS
127	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. <i>Digestive Diseases</i> , 2014, 32, 586-596.	0.8	10
128	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI est finit". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 432-439.	0.7	10
129	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	1.1	10
130	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015, 5, e010017.	0.8	9
131	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
132	When the journey from obesity to cirrhosis takes an early start. <i>Journal of Hepatology</i> , 2016, 65, 249-251.	1.8	8
133	The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 8-10.	3.7	8
134	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007.	0.8	8
135	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	1.2	8
136	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	1.4	7
137	An international survey on patterns of practice in NAFLD and expectations for therapies "The POP-NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	3.6	7
138	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	2.6	6
139	Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 183-189.	0.5	5
140	Targeting non-alcoholic fatty liver disease through 11- $\beta$ HSD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 354-356.	5.5	4
141	Improving NASH with a little help from thymomimetics. <i>Lancet</i> , 2019, 394, 1970-1972.	6.3	4
142	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020, 37, 4627-4640.	1.3	4
143	Introducing the Expert Opinion series. <i>Journal of Hepatology</i> , 2020, 73, 5.	1.8	4
144	From the Editor's Desk. <i>Journal of Hepatology</i> , 2021, 74, 1-4.	1.8	4

#	ARTICLE	IF	CITATIONS
145	Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, G942-G944.	1.6	3
146	External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. GastroHep, 2019, 1, 146-153.	0.3	3
147	From the Editor's Desk.... Journal of Hepatology, 2020, 73, 1-4.	1.8	3
148	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatology Communications, 2021, 5, 774-785.	2.0	3
149	From the Editor's Desk.... Journal of Hepatology, 2021, 75, 1-4.	1.8	3
150	From the Editor's Desk . Journal of Hepatology, 2021, 75, 757-760.	1.8	3
151	Pharmacological agents for nonalcoholic steatohepatitis. Hepatology International, 2013, 7, 833-841.	1.9	2
152	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Annals of Internal Medicine, 2013, 159, 370.	2.0	2
153	Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". Journal of Hepatology, 2016, 65, 1267-1268.	1.8	2
154	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). American Journal of Gastroenterology, 2018, 113, 443-445.	0.2	2
155	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2021, 17, 398-400.	1.0	2
156	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
157	Screening studies of transient elastography and FibroTest in the general population. The Lancet Gastroenterology and Hepatology, 2017, 2, 246.	3.7	1
158	From the Editor's Desk . Journal of Hepatology, 2021, 75, 257-260.	1.8	1
159	NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 415-417.e1.	2.3	0
160	Editorial: it is not a wide-open field for incretins -collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 611-612.	1.9	0
161	From the Editor's Desk . Journal of Hepatology, 2020, 73, 1001-1004.	1.8	0
162	From the Editor's Desk . Journal of Hepatology, 2020, 73, 475-478.	1.8	0

#	ARTICLE	IF	CITATIONS
163	From the Editor's Desk.... Journal of Hepatology, 2020, 73, 745-748.	1.8	0
164	Clinical endpoints are necessary in the interim analysis of REGENERATE â€“ Authors' reply. Lancet, The, 2020, 396, 663-664.	6.3	0
165	From the Editor's Deskâ€™. Journal of Hepatology, 2020, 73, 1299-1302.	1.8	0
166	From the Editor's Deskâ€™. Journal of Hepatology, 2020, 72, 1039-1042.	1.8	0
167	From the Editor's Desk.... Journal of Hepatology, 2020, 72, 597-600.	1.8	0
168	From the Editor's Deskâ€™. Journal of Hepatology, 2020, 73, 227-230.	1.8	0
169	Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. Hepatology, 2020, 71, 1146-1149.	3.6	0
170	From the Editor's Deskâ€™. Journal of Hepatology, 2020, 72, 379-383.	1.8	0
171	From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2020, 72, 805-808.	1.8	0
172	From the Editor's Deskâ€™. Journal of Hepatology, 2021, 74, 265-268.	1.8	0
173	From the Editor's Desk.... Journal of Hepatology, 2021, 74, 493-496.	1.8	0
174	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 765-768.	1.8	0
175	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 1005-1008.	1.8	0
176	From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2021, 74, 1277-1280.	1.8	0
177	From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2021, 75, 499-502.	1.8	0
178	From the Editorâ€™s deskâ€™. Journal of Hepatology, 2021, 75, 1013-1016.	1.8	0
179	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 75, 1261-1264.	1.8	0
180	From the Editorâ€™s Desk.... Journal of Hepatology, 2022, 76, 1-4.	1.8	0

#	ARTICLE	IF	CITATIONS
181	From the Editor's Desk.... Journal of Hepatology, 2022, 76, 257-260.	1.8	0
182	Reply. Hepatology, 2022, 76, E43-E43.	3.6	0
183	From the Editor's Desk.... Journal of Hepatology, 2022, 76, 491-494.	1.8	0
184	From the Editor's Desk.... Journal of Hepatology, 2022, 76, 759-762.	1.8	0
185	Reply. Hepatology, 2022, 76, E53-E53.	3.6	0
186	From the Editor's Desk.... Journal of Hepatology, 2022, 76, 991-994.	1.8	0